SGLT2 Inhibitors A New Standard in Diabetes Care
Received Date: Sep 02, 2024 / Published Date: Sep 30, 2024
Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a revolutionary class of medications in the management of type 2 diabetes mellitus (T2DM). These agents not only effectively lower blood glucose levels but also offer significant cardiovascular and renal benefits, thereby establishing themselves as a new standard in diabetes care. This article reviews the mechanisms of action, clinical efficacy, recent advancements, and future directions of SGLT2 inhibitors, emphasizing their comprehensive role in diabetes management.
Keywords: SGLT2 Inhibitors; Type 2 Diabetes; Cardiovascular Ben- efits; Renal Protection; Glycemic Control; Weight Management; Dia- betes Management Guidelines; Patient Safety
Citation: Jack B (2024) SGLT2 Inhibitors a New Standard in Diabetes Care. J Diabetes Clin Prac 7: 271. Doi: 10.4172/jdce.1000271
Copyright: © 2024 Jack B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 85
- [From(publication date): 0-0 - Feb 23, 2025]
- Breakdown by view type
- HTML page views: 58
- PDF downloads: 27
